Shattuck Labs Q2 FY26 net loss widens to $15.2 million; R&D expenses rise to $11.7 million

Reuters2026/08/11 10:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Shattuck posted a GAAP net loss of USD 15.2 million, widening from USD 12.5 million a year earlier, with loss per share improving to USD 0.12 from USD 0.24.
GAAP RD expense rose to USD 11.7 million from USD 8.7 million, while GAAP GA expense edged up to USD 4.5 million from USD 4.4 million.
Cash, cash equivalents and short-term investments climbed to USD 208.3 million from USD 50.5 million, with runway expected to extend into 2029.
Phase 1 data for lead DR3 blocker SL-325 showed 3.7% antidrug antibodies and TL1A-binding blockade to DR3 for over three months at ≥1 mg/kg doses.
RECEPTIVE-CD1 Phase 2b Crohn’s trial is expected to start in Q3 2026, with 12-week endoscopic response data expected in H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110615PRIMZONEFULLFEED9807330) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Shattuck Labs Q2 FY26 net loss widens to $15.2 million; R&D expenses rise to $11.7 million

You may also like

Crypto prices